Dr Daniel Hayes
Dr. Daniel F. Hayes is the Clinical Director of the Breast Oncology Program and the Stuart B. Padnos Professor of Breast Cancer Research.at the University of Michigan Comprehensive Cancer Center.
Dr. Hayes received undergraduate, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has led the breast cancer programs at DFCI (1991-1996), Georgetown University’s Lombardi Cancer Center (1996-2001), and the University of Michigan since 2001.
Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility.
He is chair of the SWOG Breast Cancer Translational Medicine Committee, and he was an member and chaired the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee. Dr. Hayes served on the ASCO Board of Directors, and served a 3 year term as President of ASCO from 2016-2018. He is a Fellow of ASCO, a Komen Scholar, and a member of the Association of American Physicians and the American Clinical and Climatologic Association. He was the inaugural recipient of the ASCO Gianni Bonadonna Award in breast cancer.